解析血小板蛋白质组以理解免疫性血小板减少症的病理生理:小鼠模型研究
研究对被动和主动免疫性血小板减少症(ITP)小鼠模型在血小板减少期及血小板计数恢复后(自然恢复或经静脉免疫球蛋白治疗,取决于模型)进行血小板蛋白质组分析,发现多数蛋白质组改变为两模型共有,但存在模型特异性蛋白动态,伴随并解释被动ITP模型中血小板聚集反应的改变。Syk的表达动态或可解释ITP患者接受福坦替尼三线及以上治疗较二线治疗出血倾向增加,该推断有待验证。作者提出血小板蛋白质组可能为ITP提供诊断和预后信息,并应在人体中开展此类研究。
要点
- 被动和主动ITP小鼠模型分别模拟人类急性/新诊断和持续性/慢性ITP阶段。
- 两模型多数血小板蛋白质组改变共有,但存在模型特异性蛋白动态。
- Syk表达动态或可解释福坦替尼三线及以上较二线治疗时出血倾向增加(待验证)。
核心结论
- 血小板蛋白质组可能为ITP提供诊断和预后信息,并应在人体中开展此类研究。
研究设计与样本
- 研究采用被动和主动临床前ITP小鼠模型,分别模拟人类急性/新诊断和持续性/慢性ITP阶段。
- 在血小板减少期和血小板计数恢复后(自然恢复或经静脉免疫球蛋白治疗,取决于模型)获取血小板蛋白质组。
主要发现
- 多数蛋白质组改变为两ITP模型共有。
- 存在模型特异性蛋白动态,伴随并解释被动ITP模型中测得的血小板聚集反应改变。
- Syk的表达动态或可解释ITP患者接受福坦替尼三线及以上较二线治疗时出血倾向增加,该推断有待验证。
临床怎么用
- 作者提出血小板蛋白质组可能为ITP提供诊断和预后信息。
- 作者提出此类研究应在人体中开展。
局限性
- Syk表达动态对ITP患者出血倾向的解释为外推至人类,且有待验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by enhanced platelet clearance and defective platelet production. Diagnosis by exclusion and trial-and-error treatment strategies is common practice, and despite the advancement in treatment options, many patients remain refractory. Although the existence of different pathophysiological entities is acknowledged, we are still far from stratifying and understanding ITP. To investigate, we sought to dissect the platelet proteome dynamics in so-called passive and active preclinical ITP mouse models, with which we propose to phenocopy respectively acute/newly diagnosed and persistent/chronic stages of ITP in humans. We obtained the platelet proteome at the thrombocytopenic stage and after platelet count recovery (reached naturally or by IVIg-treatment, depending on the model). Although most of the proteomic alterations were common to both ITP models, there were model-specific protein dynamics that accompanied and explained alterations in platelet aggregation responses, as measured in the passive ITP model. The expression dynamics observed in Syk may explain, extrapolated to humans and pending validation, the increased bleeding tendency of patients with ITP when treated with fostamatinib as third or later- as opposed to second line of treatment. We propose that the platelet proteome may give diagnostic and prognostic insights into ITP and that such studies should be pursued in humans.
引用
- Martínez-Botía P, Meinders M, De Cuyper IM, et al. Dissecting platelet proteomics to understand the pathophysiology of immune thrombocytopenia: studies in mouse models. Blood Adv. 2022. PMID: 35298626. doi:10.1182/bloodadvances.2021006438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。